---
title: Antihypertensive Drugs
type: content
phase: 1
status: complete
priority: high
tags: [antihypertensives, ACE-inhibitors, ARBs, beta-blockers, calcium-channel-blockers, diuretics, hypertension]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antihypertensive Drugs

## Introduction

Hypertension affects over 1 billion people worldwide and is a major risk factor for cardiovascular disease, stroke, and chronic kidney disease. Antihypertensive therapy reduces cardiovascular morbidity and mortality. Multiple drug classes with different mechanisms of action are available, allowing for individualized treatment based on patient characteristics and comorbidities.

## Core Concept

Blood pressure is determined by cardiac output (CO) and systemic vascular resistance (SVR):
```
BP = CO × SVR
CO = Heart Rate × Stroke Volume
```

Antihypertensive drugs work by:
1. Decreasing cardiac output (β-blockers, some CCBs)
2. Decreasing systemic vascular resistance (vasodilators, ACE-I, ARBs, CCBs)
3. Decreasing blood volume (diuretics)
4. Modulating neurohormonal systems (ACE-I, ARBs, β-blockers, central agents)

---

## ACE Inhibitors (ACE-I)

### Mechanism of Action

**Primary Mechanism**:
- Inhibit Angiotensin-Converting Enzyme (ACE)
- Block conversion of angiotensin I → angiotensin II
- Decrease angiotensin II-mediated vasoconstriction and aldosterone secretion
- Prevent bradykinin degradation → ↑bradykinin → vasodilation, dry cough

**Effects**:
- ↓Systemic vascular resistance (vasodilation)
- ↓Aldosterone → ↓sodium/water retention, ↑potassium retention
- ↓Cardiac remodeling and fibrosis
- ↓Sympathetic activation
- Renoprotective (dilate efferent > afferent arterioles → ↓glomerular pressure)

### Drug Examples

**Short-Acting**:
- **Captopril**: t½ 2 hr, dosed TID

**Intermediate-Acting**:
- **Enalapril**: Prodrug → enalaprilat, dosed BID
- **Lisinopril**: Active drug, not prodrug, dosed daily

**Long-Acting** (most commonly used):
- **Ramipril**: Dosed daily
- **Perindopril**: Dosed daily
- **Benazepril**: Dosed daily
- **Fosinopril**: Dual elimination (hepatic + renal)

### Pharmacokinetics

**Absorption**: Oral, variable bioavailability
**Distribution**: Most are prodrugs requiring hepatic activation
**Metabolism**: Hepatic (prodrugs activated)
**Excretion**:
- Primarily renal (most drugs)
- Fosinopril: Dual hepatic/renal (safe in renal failure)

**Dose Adjustment**: Required in renal impairment (except fosinopril)

### Clinical Indications

**FDA-Approved**:
1. **Hypertension** (first-line, especially with diabetes or CKD)
2. **Heart failure with reduced ejection fraction** (HFrEF)
3. **Post-MI** (especially with LV dysfunction)
4. **Diabetic nephropathy**
5. **Chronic kidney disease** (proteinuria reduction)

**Evidence-Based Benefits**:
- Reduce CV mortality in HFrEF
- Reduce progression of diabetic and non-diabetic CKD
- Reduce post-MI mortality
- Reduce LV remodeling

### Adverse Effects

**Common**:
- **Dry cough** (10-15%): Due to ↑bradykinin, most common reason for discontinuation
- **Hypotension**: Especially first-dose, volume-depleted patients
- **Hyperkalemia**: Risk increased with CKD, K+ supplements, K+-sparing diuretics

**Serious**:
- **Angioedema** (0.1-0.7%): Life-threatening, more common in African Americans
  - Due to bradykinin accumulation
  - Can occur at any time during therapy
  - Contraindicated if prior angioedema
- **Acute kidney injury**: Especially bilateral RAS, volume depletion
  - Expect SCr increase up to 30% (acceptable)
  - Hold if SCr increases >30% or hyperkalemia develops
- **Teratogenicity**: Pregnancy category D (2nd/3rd trimester)
  - Fetal renal dysgenesis, oligohydramnios, IUGR

**Rare**:
- Taste disturbances (especially captopril)
- Rash
- Neutropenia (captopril with high doses)

### Contraindications

**Absolute**:
- Pregnancy (2nd/3rd trimester)
- History of angioedema with ACE-I
- Bilateral renal artery stenosis

**Relative**:
- Unilateral RAS in solitary kidney
- Severe aortic stenosis
- Hyperkalemia (K+ >5.5)
- Severe renal impairment (individualize)

### Drug Interactions

1. **K+-sparing diuretics, K+ supplements**: Hyperkalemia risk
2. **NSAIDs**: ↓antihypertensive effect, ↑AKI risk
3. **Lithium**: ↑lithium levels (↓renal clearance)
4. **Aliskiren**: Avoid combination (↑AKI, hyperkalemia, hypotension)

### Clinical Pearls

1. **First-dose hypotension**: Start low dose, especially if volume depleted
2. **Cough management**: If bothersome, switch to ARB
3. **Renal monitoring**: Check SCr and K+ at baseline, 1-2 weeks, then periodically
4. **Acceptable SCr increase**: Up to 30% is expected and acceptable
5. **Renoprotective**: Benefits outweigh risks in CKD with proteinuria
6. **Mortality benefit**: Proven in HFrEF, post-MI

---

## Angiotensin Receptor Blockers (ARBs)

### Mechanism of Action

**Primary Mechanism**:
- Selective AT1 receptor antagonists
- Block angiotensin II effects at receptor level
- Do NOT inhibit bradykinin degradation (no cough)

**Effects**:
- Similar to ACE-I: vasodilation, ↓aldosterone, renoprotection
- Better tolerated than ACE-I (no bradykinin effects)

### Drug Examples

**All end in "-sartan"**:
- **Losartan**: First ARB, active metabolite, dosed daily-BID
- **Valsartan**: Dosed daily-BID
- **Irbesartan**: Dosed daily
- **Candesartan**: Prodrug, dosed daily
- **Telmisartan**: Longest half-life (24 hr), dosed daily
- **Olmesartan**: Dosed daily
- **Azilsartan**: Newest, most potent

### Pharmacokinetics

**Absorption**: Oral, variable bioavailability
**Metabolism**: Hepatic (CYP2C9 for losartan)
**Excretion**: Biliary > renal (unlike ACE-I)
**Dose Adjustment**: Generally not required in renal impairment

### Clinical Indications

**Same as ACE-I**:
1. Hypertension (first-line with DM or CKD)
2. Heart failure with reduced ejection fraction
3. Diabetic nephropathy
4. Post-MI with LV dysfunction

**Preferred Over ACE-I**:
- ACE-I intolerance (cough, angioedema)
- Similar efficacy, better tolerability

### Adverse Effects

**Common**:
- **Hypotension**
- **Hyperkalemia**
- **Dizziness**

**Serious**:
- **Angioedema** (less common than ACE-I, but can occur)
- **Acute kidney injury** (same mechanism as ACE-I)
- **Teratogenicity** (same as ACE-I)

**Notable**:
- **NO cough** (major advantage over ACE-I)
- Olmesartan: Associated with sprue-like enteropathy (rare)

### Contraindications

**Same as ACE-I**:
- Pregnancy
- Bilateral renal artery stenosis
- History of angioedema (relative)

### Drug Interactions

**Similar to ACE-I**:
- K+-sparing diuretics, K+ supplements
- NSAIDs
- Lithium
- Aliskiren

### Clinical Pearls

1. **Alternative to ACE-I**: Use if ACE-I causes cough
2. **No cough**: Major advantage in tolerability
3. **Less angioedema**: But still possible, use caution
4. **Similar efficacy**: To ACE-I in most indications
5. **No combination**: ACE-I + ARB NOT recommended (↑harm, no benefit)

---

## Beta-Blockers

### Mechanism of Action

**Primary Mechanism**:
- Competitive antagonism of β-adrenergic receptors
- Block catecholamine effects

**Cardiovascular Effects**:
- ↓Heart rate (negative chronotropy)
- ↓Contractility (negative inotropy)
- ↓AV conduction (negative dromotropy)
- ↓Cardiac output
- ↓Renin release (β1 blockade)
- ↓Myocardial oxygen demand

### Classification

**By Selectivity**:

**Non-Selective** (β1 + β2):
- **Propranolol**: Lipophilic, CNS effects
- **Nadolol**: Hydrophilic, long-acting
- **Timolol**: Ophthalmic use

**β1-Selective** (Cardioselective):
- **Metoprolol**: Succinate (ER) or tartrate (IR)
- **Atenolol**: Hydrophilic, renal excretion
- **Bisoprolol**: Long-acting
- **Nebivolol**: Also causes NO-mediated vasodilation
- **Esmolol**: Ultra-short acting (IV only)

**Note**: Selectivity is dose-dependent; lost at higher doses

**Mixed α/β Blockers**:
- **Labetalol**: α1 + non-selective β, IV/PO
- **Carvedilol**: α1 + non-selective β, antioxidant properties

**With Intrinsic Sympathomimetic Activity (ISA)**:
- **Pindolol**: Partial agonist activity
- **Acebutolol**: β1-selective with ISA
- Note: Less bradycardia, less mortality benefit

### Pharmacokinetics

**Lipophilic** (cross BBB):
- Propranolol, metoprolol, carvedilol
- Hepatic metabolism
- CNS side effects more common

**Hydrophilic** (don't cross BBB):
- Atenolol, nadolol
- Renal excretion
- Require dose adjustment in renal failure

### Clinical Indications

**Cardiovascular**:
1. **Hypertension** (not first-line except with specific indications)
2. **Heart failure with reduced EF** (metoprolol, bisoprolol, carvedilol)
   - Reduce mortality in HFrEF
   - Start low, titrate slowly
3. **Post-myocardial infarction** (reduce mortality)
4. **Angina** (reduce myocardial oxygen demand)
5. **Arrhythmias**: Rate control (AF, SVT)
6. **Aortic dissection**: Reduce shear stress

**Other Indications**:
- Essential tremor (propranolol)
- Performance anxiety (propranolol)
- Migraine prophylaxis (propranolol)
- Hyperthyroidism (symptom control)
- Glaucoma (timolol - topical)
- Portal hypertension/variceal bleeding prophylaxis (propranolol)

### Adverse Effects

**Cardiovascular**:
- **Bradycardia**
- **Hypotension**
- **AV block**
- **Heart failure exacerbation** (especially if not for HFrEF)

**Metabolic**:
- **Hyperglycemia**: Masks hypoglycemia symptoms (except tremor)
- **Hypertriglyceridemia**
- **↑LDL, ↓HDL** (non-selective more than selective)

**Respiratory**:
- **Bronchospasm**: Due to β2 blockade (non-selective)
- Caution in asthma/COPD (use β1-selective if needed)

**CNS**:
- Fatigue, depression, insomnia
- Nightmares (lipophilic agents)
- Sexual dysfunction

**Other**:
- Cold extremities (peripheral vasoconstriction)
- Raynaud's phenomenon
- Impaired exercise tolerance

### Contraindications

**Absolute**:
- Sinus bradycardia (<50 bpm)
- Sick sinus syndrome (without pacemaker)
- 2nd/3rd degree AV block (without pacemaker)
- Decompensated heart failure
- Severe asthma

**Relative**:
- COPD (use β1-selective with caution)
- Peripheral vascular disease
- Diabetes (masks hypoglycemia)

### Drug Interactions

1. **Calcium channel blockers** (verapamil, diltiazem):
   - Additive negative chronotropy/inotropy
   - Risk of bradycardia, AV block, HF
2. **Digoxin**: Additive AV nodal suppression
3. **Antiarrhythmics**: Additive cardiac depression
4. **Clonidine**: Never stop β-blocker first (rebound HTN)

### Withdrawal

**Rebound Phenomenon**:
- Abrupt withdrawal can cause:
  - Rebound hypertension
  - Tachycardia
  - Angina exacerbation
  - MI
- **Taper over 1-2 weeks** when discontinuing

### Clinical Pearls

1. **Start low, go slow**: Especially in HF
2. **β1-selective preferred**: In asthma/COPD if needed
3. **Mortality benefit**: In HFrEF, post-MI
4. **Not first-line HTN**: Unless specific indication (CAD, HF, post-MI)
5. **Taper on discontinuation**: Prevent rebound
6. **Carvedilol in HF**: Superior to metoprolol in some studies

---

## Calcium Channel Blockers (CCBs)

### Mechanism of Action

**Primary Mechanism**:
- Block L-type voltage-gated calcium channels
- Prevent Ca2+ entry into cells

**Effects**:
- Vascular smooth muscle: Vasodilation
- Cardiac muscle: ↓contractility (non-dihydropyridines)
- SA/AV nodes: ↓automaticity, ↓conduction (non-dihydropyridines)

### Classification

**Dihydropyridines (DHPs)**:
- More vascular selective
- Potent peripheral vasodilation
- Minimal cardiac effects
- Names end in "-dipine"

**Examples**:
- **Amlodipine**: Long-acting, once daily
- **Nifedipine**: IR (avoid), XL (preferred)
- **Felodipine**: Long-acting
- **Nicardipine**: IV form available

**Non-Dihydropyridines**:
- More cardiac selective
- ↓HR, ↓contractility, ↓AV conduction
- Less vasodilation than DHPs

**Examples**:
- **Verapamil**: Phenylalkylamine class
- **Diltiazem**: Benzothiazepine class

### Pharmacokinetics

**Absorption**: Well absorbed orally
**Metabolism**: Extensive hepatic (CYP3A4)
**Excretion**: Biliary/fecal
**Half-lives**:
- Amlodipine: 30-50 hours (longest)
- Nifedipine XL: 24 hours
- Diltiazem: 3-7 hours (ER formulations available)
- Verapamil: 4-12 hours (ER formulations available)

### Clinical Indications

**Dihydropyridines**:
1. **Hypertension** (first-line, especially elderly)
2. **Angina** (vasospastic, stable)
3. **Raynaud's phenomenon**

**Non-Dihydropyridines**:
1. **Hypertension**
2. **Angina**
3. **Arrhythmias**: Rate control in AF, SVT
4. **PSVT**: Acute termination (adenosine alternative)

### Adverse Effects

**Dihydropyridines**:
- **Peripheral edema** (ankle swelling, not from fluid retention)
- **Flushing**
- **Headache**
- **Reflex tachycardia** (especially nifedipine IR)
- **Gingival hyperplasia**

**Non-Dihydropyridines**:
- **Bradycardia**
- **AV block**
- **Constipation** (especially verapamil)
- **Negative inotropy** (avoid in HFrEF)
- **Edema** (less than DHPs)

**All CCBs**:
- Hypotension
- Dizziness

### Contraindications

**Dihydropyridines**:
- Relative: Severe aortic stenosis

**Non-Dihydropyridines**:
- Heart failure with reduced EF
- Sick sinus syndrome
- 2nd/3rd degree AV block
- Severe bradycardia
- Concomitant β-blocker (relative)

### Drug Interactions

1. **CYP3A4 Inhibitors**:
   - ↑CCB levels (grapefruit juice, azoles, macrolides)
   - Risk of hypotension, bradycardia
2. **CYP3A4 Inducers**: ↓CCB levels (rifampin, phenytoin)
3. **β-blockers + non-DHP CCBs**:
   - Additive negative chronotropy/inotropy
   - Risk of bradycardia, AV block, HF
4. **Statins**: ↑statin levels (CYP3A4 interaction)
5. **Digoxin**: ↑digoxin levels (especially verapamil)

### Clinical Pearls

1. **Edema is vascular**: Not fluid overload; diuretics don't help
2. **Add ACE-I**: Can reduce CCB-induced edema
3. **Avoid nifedipine IR**: Risk of reflex tachycardia, CV events
4. **Constipation with verapamil**: Common, prophylactic stool softeners
5. **Amlodipine preferred**: Once-daily, well-tolerated, long safety record
6. **Non-DHPs for rate control**: Alternative to β-blockers

---

## Diuretics

### Thiazide and Thiazide-Like Diuretics

**Mechanism of Action**:
- Inhibit Na+-Cl- cotransporter in distal convoluted tubule
- ↓Sodium and water reabsorption
- ↓Blood volume, ↓cardiac output
- Chronic: ↓SVR (vasodilation)

**Drug Examples**:
- **Hydrochlorothiazide (HCTZ)**: 12.5-50 mg daily
- **Chlorthalidone**: 12.5-25 mg daily (longer acting, more potent)
- **Indapamide**: 1.25-2.5 mg daily (thiazide-like)
- **Metolazone**: More effective in renal impairment

**Pharmacokinetics**:
- Oral absorption
- Duration: HCTZ 6-12 hr, Chlorthalidone 24-72 hr
- Renal excretion

**Clinical Indications**:
1. **Hypertension** (first-line)
2. **Heart failure** (mild volume overload)
3. **Nephrolithiasis** (calcium stones - ↓urinary calcium)
4. **Nephrogenic diabetes insipidus**
5. **Osteoporosis prevention** (↓urinary calcium loss)

**Adverse Effects**:
- **Hypokalemia** (most common)
- **Hyponatremia**
- **Hyperuricemia** → gout
- **Hyperglycemia** (↓insulin secretion)
- **Hyperlipidemia** (↑LDL, ↑TG)
- **Hypercalcemia**
- **Hypomagnesemia**
- **Sexual dysfunction** (erectile dysfunction)

**Contraindications**:
- Sulfa allergy (relative)
- Severe renal impairment (ineffective if GFR <30)
- Anuria

**Clinical Pearls**:
1. **First-line for HTN**: Especially elderly, African Americans
2. **Chlorthalidone > HCTZ**: More potent, longer-acting, better outcomes
3. **Monitor electrolytes**: K+, Na+, Mg2+ at baseline and periodically
4. **Low doses effective**: 12.5-25 mg often sufficient
5. **Calcium-sparing**: Only diuretic that ↓urinary calcium

### Loop Diuretics

**Mechanism of Action**:
- Inhibit Na+-K+-2Cl- cotransporter in thick ascending limb of loop of Henle
- Most potent diuretics
- ↓Calcium and magnesium reabsorption

**Drug Examples**:
- **Furosemide**: 20-400 mg daily, IV/PO
- **Bumetanide**: 0.5-10 mg daily, more bioavailable
- **Torsemide**: 5-200 mg daily, better bioavailability
- **Ethacrynic acid**: Non-sulfa alternative

**Pharmacokinetics**:
- IV/PO administration
- Furosemide oral bioavailability: 10-90% (variable)
- Torsemide/bumetanide: Better, more consistent absorption
- Short duration: 4-6 hours

**Clinical Indications**:
1. **Heart failure** (acute and chronic)
2. **Pulmonary edema**
3. **Renal failure** (maintain urine output)
4. **Hypercalcemia**
5. **Severe hypertension** (resistant, with renal impairment)

**Adverse Effects**:
- **Hypokalemia**
- **Hyponatremia**
- **Hypocalcemia**
- **Hypomagnesemia**
- **Metabolic alkalosis**
- **Hyperuricemia**
- **Ototoxicity** (high doses, rapid IV)
- **Hyperglycemia**

**Drug Interactions**:
1. **Aminoglycosides**: ↑ototoxicity
2. **Cisplatin**: ↑nephrotoxicity, ↑ototoxicity
3. **NSAIDs**: ↓diuretic effect
4. **Digoxin**: Hypokalemia → ↑digoxin toxicity

**Clinical Pearls**:
1. **Short-acting**: Requires multiple daily doses or continuous infusion
2. **Torsemide preferred**: Better bioavailability, once-daily dosing
3. **IV in acute HF**: Faster, more reliable
4. **Diuretic resistance**: Use combination with thiazides
5. **Monitor electrolytes**: Especially K+, Mg2+
6. **Replete K+ and Mg2+**: Before and during therapy

### Potassium-Sparing Diuretics

**Aldosterone Antagonists**:

**Mechanism**: Block mineralocorticoid receptors

**Examples**:
- **Spironolactone**: Non-selective (also blocks androgen/progesterone receptors)
- **Eplerenone**: Selective (fewer hormonal side effects)

**Indications**:
1. **Heart failure** (HFrEF): Mortality benefit
2. **Resistant hypertension**
3. **Primary hyperaldosteronism**
4. **Cirrhosis with ascites**

**Adverse Effects**:
- Hyperkalemia (main concern)
- Gynecomastia, breast tenderness (spironolactone)
- Menstrual irregularities
- Sexual dysfunction

**ENaC Inhibitors**:

**Mechanism**: Block epithelial sodium channels in collecting duct

**Examples**:
- **Amiloride**
- **Triamterene**

**Indications**:
- Hypertension (combination products)
- Lithium-induced nephrogenic DI

**Clinical Pearls**:
1. **Mortality benefit**: Spironolactone/eplerenone in HFrEF
2. **Weak diuretics**: Used with thiazides/loops
3. **Monitor K+**: Risk of hyperkalemia, especially with ACE-I/ARB
4. **Eplerenone preferred**: If gynecomastia with spironolactone

---

## Other Antihypertensive Classes

### Direct Renin Inhibitors

**Aliskiren**:
- Directly inhibits renin
- ↓Angiotensin I and II formation
- Limited use due to lack of superiority and safety concerns
- **Do not combine with ACE-I or ARB**

### Alpha-1 Blockers

**Examples**: Doxazosin, Prazosin, Terazosin

**Mechanism**: Block α1-adrenergic receptors → vasodilation

**Indications**:
- Hypertension (not first-line)
- BPH (dual benefit)

**Adverse Effects**:
- First-dose hypotension
- Orthostatic hypotension
- Dizziness
- Reflex tachycardia

**Clinical Pearls**:
- Take first dose at bedtime
- Not recommended as monotherapy for HTN
- Useful in men with BPH + HTN

### Central Alpha-2 Agonists

**Examples**:
- **Clonidine**: PO, transdermal patch
- **Methyldopa**: Safe in pregnancy
- **Guanfacine**: ADHD treatment

**Mechanism**:
- Stimulate α2-receptors in brainstem
- ↓Sympathetic outflow

**Indications**:
- Resistant hypertension
- Pregnancy (methyldopa)
- ADHD (guanfacine)

**Adverse Effects**:
- Dry mouth
- Sedation
- Rebound hypertension (if stopped abruptly)
- Positive Coombs test (methyldopa)

**Clinical Pearls**:
- Methyldopa: DOC for chronic HTN in pregnancy
- Taper clonidine to avoid rebound
- Clonidine patch changed weekly

### Direct Vasodilators

**Hydralazine**:
- Direct arteriolar vasodilation
- Reflex tachycardia, fluid retention
- Used in: Resistant HTN, pregnancy, HF (with nitrates)
- Adverse: Drug-induced lupus (slow acetylators), headache

**Minoxidil**:
- K+ channel opener → hyperpolarization → vasodilation
- Very potent
- Reserved for resistant hypertension
- Adverse: Hypertrichosis, pericardial effusion
- Requires β-blocker + loop diuretic

---

## Treatment Guidelines and Approach

### JNC 8 / ACC/AHA Guidelines

**BP Goals**:
- General population: <130/80 mmHg
- Elderly (>65): <130/80 (if tolerated)
- DM/CKD: <130/80

**First-Line Agents** (choose based on comorbidities):
1. Thiazide diuretics
2. ACE inhibitors
3. ARBs
4. Calcium channel blockers

### Compelling Indications

**Heart Failure (HFrEF)**:
- ACE-I or ARB
- β-blocker (metoprolol, bisoprolol, carvedilol)
- Aldosterone antagonist
- Diuretic (loop for volume)

**Post-MI**:
- β-blocker
- ACE-I
- Aldosterone antagonist (if EF <40%)

**Diabetes**:
- ACE-I or ARB (first-line)
- Additional agents as needed

**CKD with Proteinuria**:
- ACE-I or ARB (first-line)

**Elderly**:
- Thiazide or CCB often preferred

**African Americans**:
- CCB or thiazide often more effective
- ACE-I/ARB less effective as monotherapy

**Pregnancy**:
- Methyldopa, labetalol, nifedipine
- **Avoid**: ACE-I, ARB

### Combination Therapy

**Preferred Combinations**:
1. ACE-I/ARB + CCB
2. ACE-I/ARB + thiazide
3. CCB + thiazide
4. β-blocker + dihydropyridine CCB

**Avoid**:
- ACE-I + ARB (no benefit, ↑harm)
- β-blocker + non-dihydropyridine CCB (bradycardia, HF)
- Dual renin-angiotensin blockade

---

## Clinical Pearls - Summary

1. **Start with one drug**: Titrate to maximum before adding second
2. **Compelling indications**: Guide first-line choice
3. **ACE-I or ARB**: Not both; ARB if cough with ACE-I
4. **Monitor**: BP, HR, electrolytes, renal function
5. **Thiazides**: Chlorthalidone preferred over HCTZ
6. **β-blockers**: Not first-line unless HF, CAD, or post-MI
7. **CCBs**: Good for elderly, isolated systolic HTN
8. **Lifestyle**: Diet, exercise, weight loss, sodium restriction equally important
9. **Adherence**: Simplify regimen (once-daily dosing, fixed-dose combinations)
10. **Home BP monitoring**: Confirms diagnosis, assesses control

---

## Key Takeaways

1. **Multiple drug classes** available with different mechanisms
2. **Thiazides, ACE-I/ARB, CCBs** are first-line agents
3. **Compelling indications** (HF, DM, CKD, post-MI) guide therapy
4. **ACE-I/ARB** provide renoprotection and mortality benefit in specific populations
5. **β-blockers** reduce mortality in HFrEF and post-MI
6. **CCBs** effective in elderly and African Americans
7. **Monitor electrolytes** especially with diuretics and ACE-I/ARB
8. **Avoid ACE-I/ARB combination**
9. **Individualize therapy** based on patient characteristics and comorbidities
10. **Lifestyle modifications** essential adjunct to pharmacotherapy

---

## References

1. Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018.
2. James PA, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014.
3. Katzung's Basic & Clinical Pharmacology, 15th Edition
4. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
5. ESC/ESH Guidelines for the management of arterial hypertension, 2018
